You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Peripheral FAAH as a target for novel analgesics

    SBC: Anteana Therapeutics Inc            Topic: NIDA

    DESCRIPTIONprovided by applicantPain management is a significant unmet medical needAnandamide is an endocannabinoid mediator that plays important roles in the regulation of painPrevious work has shown that endocannabinoid receptors located outside the central nervous systemCNSexert a powerful regulatory control over pain initiationThe biological actions of anandamide are stopped by the enzymefatty ...

    STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  2. A novel anti gonorrhea immunotherapeutic

    SBC: Planet Biotechnology Incorporated            Topic: NIAID

    Antimicrobial resistance is a major public health problem worldwide Neisseria gonorrhoeae Ng the causative agent of the sexually transmitted infection gonorrhea has become multidrug resistant and has achieved superbug status Novel therapeutics against Ng are urgently needed Complement C is a key arm of innate immune defenses A mechanism used by several pathogens including Ng to esca ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  3. Infection Site Targeted Antitoxin Antibody (ISTAb) against Bacillus anthracis

    SBC: Integrated Biotherapeutics, Inc.            Topic: r

    Project Summary The Gram positive bacterium Bacillus anthracis is a very strong candidate for potential bioweaponizationand believed to have actually been weaponized by the former Soviet UnionAnthrax spores are readily found in nature or produced in the laboratoryare resistant to harsh conditionsand can survive for a long time in the environmentThe microscopic spores could be formulated in powder ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  4. In Vivo Editing for Hemophilia Gene Therapy

    SBC: GENVEC, INC.            Topic: 100

    Project Summary The exceptional promise of gene therapy for hemophilia has been shown in recent studies that result in long term correction of factor IX deficiency via hepatic transduction with an adeno associated vector AAV In spite of this watershed event in the history of the gene therapy field there presently exist barriers to the fullest implementation of hemophilia gene therapy The li ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  5. Broadly Protective Bispecific Antibodies for Treatment of Ebola Virus Disease

    SBC: Integrated Biotherapeutics, Inc.            Topic: NIAID

    PROJECT SUMMARY The family of Filoviridae consisting of five ebolaviruses and two marburgviruses are causative agents of severe hemorrhagic fever with human case fatality rates ofTheepidemic of Ebola virus disease in West Africa was unprecedented both in geographic scope and size and highlighted the extent of the threat filoviruses could pose to global public health and the urgent need for develop ...

    STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  6. Epigenetic Markers and Sustained Cytoprotection for Stroke Treatment

    SBC: ZYMO RESEARCH CORP.            Topic: 101

    PROJECT SUMMARY ABSTRACT Stroke injury is a process that occurs over a long duration with pathologic changes that result in long term neurologic dysfunction For stroke there exists an important need for a strategy that can provide safe and efficacious stabilization to the hypoperfused brain and initialize long lasting endogenous neuroprotection for prevention of long term neurologic dysfunction ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  7. Automated electrophysiological analysis of neural circuitry using a novel nano electrode array for intracellular recording of membrane potential

    SBC: CYION TECHNOLOGIES LLC            Topic: 101

    Summary Nervous systems process information by integrating the electrical activity of neurons in complex networks The alterations in the flow of electrical activity through neuronal networks of the brain play a causal role in the pathogenesis and or the appearance of symptoms of neurodegenerative and psychiatric diseases A fundamental goal of BRAIN Initiative is therefore to elucidate how the ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  8. Gold nanoparticle laser warming of cryopreserved zebrafish embryos

    SBC: NANOCOMPOSIX, INC.            Topic: OD

    Project Summary Abstract In the past decade laboratories around the world have produced tens of thousands of mutant transgenic and wild type zebrafish lines for a wide range of genetic and biomedical research Maintaining all of these valuable genotypes is expensive risky and beyond the capacity of even the largest stock centers Cryopreservation of zebrafish sperm eggs and embryos is vital ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  9. Next Generation Regenerative Therapy with Pim Enhanced Cardiac Progenitor Cells

    SBC: CardioCreate, Inc.            Topic: NHLBI

    PROJECT SUMMARY Myocardial regenerative therapy is poised to revolutionize the way heart failure is treated but further improvements and enhanced products are needed to make this therapy truly safe and efficacious Our company CardioCreate Inc has pioneered the use of genetic engineering to enhance the regenerative potential of human Cardiac Progenitor Cells CPCs intended for autologous the ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  10. Assessment of the glucagon receptor blocker REMD-477 on insulin requirements in type 1 diabetes

    SBC: REMD BIOTHERAPEUTICS INC.            Topic: NIDDK

    DESCRIPTIONprovided by applicantFast TrackInsulin remains the primaryand often the onlytreatment for typediabetes mellitusT DHowever it is associated with chronic iatrogenic hyperinsulinemiasecondary hyperlipidemiahigher incidence and severity of cardiovascular complicationsand life threatening hypoglycemia eventsA higher mortalityvsdue to cardiovascular complications were reported in insulin trea ...

    STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government